ARTICLE | Discovery & Translation
BioCentury’s roundup of translational innovations
By Danielle Golovin, Senior Biopharma Analyst
February 24, 2024 1:14 AM UTC


Amphista Therapeutics Ltd. unveiled a new type of molecular glue degrader that it made more potent by engineering it to bind two domains on the same target protein.
In Nature, the Amphista team, in collaboration with University of Dundee and others, described two “intramolecular bivalent glue” degraders that bind to the target BRD4 at two different sites, changing its conformation and allowing an E3 ubiquitin ligase to bind and promote its degradation. The two glues recruit different ligases, DCAF16 and DCAF11…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651512/science-spotlight-amphista-s-molecular-glues-gene-therapy-for-ftd-als-and-more